Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID-19 severe or critically meta-analysis

Darazam (COVIFERON Interferon beta-1a)
  NCT04343768		 RCTinterferonstandard of careCOVID-19 severe or criticallysome concern
20/20 suggested
  • suggested 1.4-fold increase in clinical improvement,clinical improvement (time to event analysis only) with a moderate degree of certainty due to some concern in risk of bias
Darazam (COVIFERON Interferon beta-1b)
  NCT04343768		 RCTIFN beta-1bstandard of careCOVID-19 severe or criticallysome concern
20/20 inconclusive
    Rahmani
          IRCT20100228003449N2    		 RCTIFN beta-1bstandard of careCOVID-19 severe or criticallysome concern
    		40/40 conclusif
    • demonstrated 2.4-fold increase in clinical improvement (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias
    1 study excluded by filtering options (1 RCT / 0 OBS)

    PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
    Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

     

    - About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons